The 60 references in paper S. Avdeev N., N. Trushenko V., С. Авдеев Н., Н. Трушенко В. (2016) “Новые перспективы в лечении хронической обструктивной болезни легких: в фокусе – аклидиния бромид // New perspectives in therapy of chronic obstructive pulmonary disease: revolving around aclidinium bromide” / spz:neicon:pulmonology:y:2015:i:6:p:725-735

1
Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмоноло* гия. 2014; 3: 15–54.
(check this in PDF content)
2
GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2015. Available from http:// www.goldcopd.org/
(check this in PDF content)
3
Айсанов З.Р., Новиков Ю.К. Антихолинергические препараты в лечении хронической обструктивной болезни легких.Трудный пациент.2012; 10 (5): 9–13.
(check this in PDF content)
4
Архипов В.В. Клиническая фармакология антихолинергических препаратов Практическая пульмонология. 2014; 2: 32–39.
(check this in PDF content)
5
Ненашева Н.М. Новые возможности достижения контроля астмы с помощью тиотропия бромида. Эф* фективная фармакотерапия.2014; 29: 4–13.
(check this in PDF content)
6
Трофименко И.Н., Черняк Б.А. Влияние бронходилататоров на бронхиальную гиперреактивность при хронической обструктивной болезни легких. Сибирский медицинский журнал.2014; 7: 67–70.
(check this in PDF content)
7
Трофимов В.И. Холинолитики в лечении больных хронической обструктивной болезни легких. Доктор.ру. 2010; 6 (57): 50–53.
(check this in PDF content)
8
Gavalda A., Ramos I., Carcasona C. et al. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulm. Pharmacol. Ther. 2014; 28 (2): 114–121.
(check this in PDF content)
9
Milara J., Gabarda E., Gavalda A. et al. An assessment of the functional profile of aclidinium in human bronchi and left atria.Eur. Respir. J. 2011; 38: 859.
(check this in PDF content)
10
Rogliani P., Calzetta L., Ora J. et. al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.Eur. J. Pharmacol. 2015; 761: 383–390.
(check this in PDF content)
11
Ni H., Soe Z., Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2014, Sep. 19; CD010509.
(check this in PDF content)
12
De la Motte S., Beier J., Schmid K. et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.Int. J. Clin. Pharmacol. Ther. 2012; 50 (6): 403–412.
(check this in PDF content)
13
Jansat J.M., Lamarca R., de Miquel G. et al. Safety and pharmacokinetics of single dose of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int. J. Clin. Pharmacol. Ther.2009; 47 (7): 460–468.
(check this in PDF content)
14
Lopez-Campos J.L., Calero C., Lopez-Ramirez C. et al. Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Preference and Adherence.2015; 9: 95–104.
(check this in PDF content)
15
Schmid K., Pascaual S., Garcia Gil. E. et al. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-labeled, single-dose clinical trial. Clin. Ther. 2010; 32 (10): 1798–1812.
(check this in PDF content)
16
Sun S.X., Mocarski M., Dixit S. et al. Prevalence of renal impairment in COPD patients treated with aclidinium bromide or tiotropium bromide. 10.1164./arjccm-conference.2015.191.1._Meeting Abstracts. A5740.
(check this in PDF content)
17
Авдеев С.Н. Базисный препарат для терапии хронической обструктивной болезни легких. Consilium Medicum. 2011; 13 (3): 15–20.
(check this in PDF content)
18
Kerwin E.M., D`Urzo A.D., Gelb A.F. et al. ACCORD I study investigators. Efficacy and safety of 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9 (2): 90–101.
(check this in PDF content)
19
Jones P.W., Singh D. Bateman E.D. et al. Efficacy and safety of treatment with twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40: 830–836.
(check this in PDF content)
20
Rennard S.I., Scanlon P.D., Ferguson G.T. et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chromic obstructive pulmonary disease patients. Clin. Drug Invest. 2013; 33 (12): 893–904.
(check this in PDF content)
21
Gelb A. Tashkin D.P. Make B.J. et al. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir. Med.2013; 197 (12): 1957–1965.
(check this in PDF content)
22
D`Urzo A., Kerwin E., Rennard S. et al. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD. 2013; 10 (4): 500–510.
(check this in PDF content)
23
Verkindre C., Fukuchi Y., Flemale A. et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonists, in COPD patients. Respir. Med. 2010; 104 (10): 1482–1489.
(check this in PDF content)
24
Kerwin E.M., Jones P.W., D`Urzo A.D. et al. Efficacy of twice-daily aclidinium bromide 400 mg in subgroups of patients with COPD. Am. J. Crit. Care Med. 2013; 187.1. A4265.
(check this in PDF content)
25
Watz H., Beeh K.M., Magnussen H. et al. Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD. Eur. Respir. J. 2013; 42: 4633.
(check this in PDF content)
26
Santus P., Radovanovic D., Marco F.D. et al. Acute effect of aclidinium bromide on hyperinflation and lung volume distribution in patients with severe COPD. 10.1164./arjccmconference.2015.191.1._Meeting Abstracts. A5736.
(check this in PDF content)
27
Beeh K.M., Watz H., Puente-Mastu L. et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulm. Med. 2014; 14: 209–221.
(check this in PDF content)
28
Maltais F., Celli B., C`asaburi R. et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.Respir. Med.2011; 105: 580–587.
(check this in PDF content)
29
McGarvey L., Morice A., Smith J. et al. The effect of twicedaily aclidinium bromide on cough and sputum in patients with COPD: results from phase III studies Eur. Respir. J. 2014; 44: 920.
(check this in PDF content)
30
Cortijo J., Mata M., Milara J. et al. Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways. Eur. Respir. J. 2011; 37: 244–254.
(check this in PDF content)
31
Beier J., Kirsten A.-M., Mroz R. et al. Efficacy and safety of Aclidinium bromide compared with placebo and Tiotropium in patients with moderate – to – severechronic obstructive pulmonary disease: results from a 6-week randomized controlled phase IIIb study. COPD. 2013; 10 (4): 511–522.
(check this in PDF content)
32
Partidge M.R., Karlsson N., Small I.R. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr. Med. Res. Opin.2009; 25: 2043–2048.
(check this in PDF content)
33
Higgins V., Broomfield S., Pollard R. et al. Impact of morning symptoms on the working lives of COPD patients. Birmingham, UK: International Conference of Chronic Obstructive Pulmonary Disease. 2012. Abstract.
(check this in PDF content)
34
Small M., Broomfield S., Pollard R. et al. Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities. Eur. Respir. J. 2012; 40 (56): 3476.
(check this in PDF content)
35
Omachi T.A., Blanc P.D., Claman D.M. et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012; 13 (5): 476–483.
(check this in PDF content)
36
Fuhr R., Magnussen H., Sarem K. et al. Efficacy and safety of aclidinium bromide 400 mg twice daily compared with placebo and tiotripium in patients with moderate-to-severe COPD. Chest. 2012; 141: 745–752.
(check this in PDF content)
37
Marth K., Schuller E., Pohl W. Improvements in patientreported outcomes: a prospective, non-interventional study with aclidinium bromide for treatment of COPD. Respir. Med. 2015; 109: 616–624.
(check this in PDF content)
38
Roche N., Chavannes N.H., Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir. Res.2013; 14: 112–119.
(check this in PDF content)
39
Joos G.F., Schelfhout V.J., Pauwels R.A. et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir. Med. 2010; 104 (6): 865–872.
(check this in PDF content)
40
Jones P.W., Rennard S.I., Agusti A. et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir. Res.2011; 12: 55.
(check this in PDF content)
41
Kew K.M., Dias S., Cates C.J. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a net-work meta-analysis. Cochrane Database Syst. Rev. 2014. DOI: 10.1002/14651858.CD010844.pub2.
(check this in PDF content)
42
Mroz R.M., Pilar Ausin M., Lamarca R. et al. Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification. Eur. Respir. J. 2014; 44: 891.
(check this in PDF content)
43
Моисеев С.В. Бронходилататоры при ХОБЛ: длительно действующие антихолинергические препараты или агонисты β2-адренорецепторов? Клиническая фармако* логия и терапия.2011; 20 (5): 8–10.
(check this in PDF content)
44
Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv. Ther. 2013; 30 (4): 354–368.
(check this in PDF content)
45
Wedzicha J.A., Donaldson G., Chuecos F. et al. Effect of aclidinium bromide on exacerbations in patients with moderate – to severe COPD: pooled analysis of phase III studies. Eur. Respir. J. 2014; 44: 1888.
(check this in PDF content)
46
Oba Y., Lone A.L. Comparative efficacy of long-acting musacarinic antagonists in preventing COPD exacebations: a network meta-analysis and meta-regression. Ther. Adv. Respir. Dis.2015; 9 (1): 3–15.
(check this in PDF content)
47
Karabis A., Mocarski M., Eljgelhoven I. et al. Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years. Clin. Econom. Outcom. Res.2014; 6: 175–185.
(check this in PDF content)
48
Lambers C., Hostettler K., Miglino N. et al. Aclidinium bromide reduces epithelial-mesenchymal transition of human COPD epithelial cells.Eur. Respir. J.2013; 42: 253.
(check this in PDF content)
49
Lambers C., Qi Y., Papakonstantinou E. et al. Aclidinium bromide reduces extracellular matrix deposition by COPDderived mesenchymal cells. Eur. Respir. J. 2013; 42: 3036.
(check this in PDF content)
50
Milara J., Serrano A., Peiro T. et al. Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transition.Eur. Respir. J. 2013; 41: 1264–1274.
(check this in PDF content)
51
Milara J., Peiro T., Peiro T. et al. Effects of aclidinium on cigarette smoke-induced fibroblast activation in vitro. Eur. Respir. J. 2011; 38 (55): 851.
(check this in PDF content)
52
Dominguez-Fandos D., Ferrer E., Puig-Pey R. et al. Effects of aclidinium bromide in a cigarette smoke-exposed Guinea pig model of chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2014; 50 (2): 337–346.
(check this in PDF content)
53
Jones P.W. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Intern. J. COPD. 2015; 10: 677–687.
(check this in PDF content)
54
Newman S.P., Sutton D.J., Segarra R. et al. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009; 78 (3): 322–328.
(check this in PDF content)
55
Block K., Fyrnys B. Impact of different inhalation volumes on the aerodynamics of aclidinium bromide delivered through the Genuair®inhaler. Am. J. Crit. Care Med.2010; 181: A4467.
(check this in PDF content)
56
Leidy N.K., Wilcox T.K., Jones P.W. et al. EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary.Am. J. Resp. Crit. Care Med.2011; 183 (3): 323–329.
(check this in PDF content)
57
Palen J., Ginko T., Kroker A. et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Exp. Opin. Drug Deliv. 2013; 10 (8): 1023–1031.
(check this in PDF content)
58
Donohue J., Rennard S., Celli B. et al. Safety and tolerability of aclidinium bromide in patients with COPD: pooled results from long-term phase III studies. Chest. 2012; 142 (4): 688A.
(check this in PDF content)
59
Lasseter K.C., Aubets J., Chuecos F. et al. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J. Clin. Pharmacol. 2010; 51 (6): 923–932.
(check this in PDF content)
60
Chapman K.R., Beck E., Alcaide D. et al. Overall and cardiovascular safety of aclidinium bromide in patients with Авдеев С.Н., Трушенко Н.В. Новые перспективы в лечении ХОБЛ: в фокусе – аклидиния бромид COPD: results of a pooled analysis.Eur. Respir. J.2014; 44: 893.
(check this in PDF content)